Background/Objectives:Cardiac metastases (CM) represent a rare manifestation of neuroendocrine neoplasms (NEN). Detailed clinical characteristics and significance remain understudied.Methods:We retrospectively evaluated 1201 patients with NEN treated at an ENETS Center of Excellence to determine prevalence, clinical features, and outcomes of cardiac metastases. CM were identified in 15 patients (prevalence 1.25%) through multimodal imaging, incorporating somatostatin receptor positron emission tomography/computed tomography (SSTR PET/CT). Metachronous CM occurrence accounted for 93% of cases.Results:The majority of patients showed well-differentiated tumors (G1/G2), with ileum being the most frequent site of origin. Clinical symptoms attributable to CM were observed in 27% of affected patients. Following CM detection, therapeutic management was adjusted in 73% of cases, most frequently by initiating peptide receptor radionuclide therapy (PRRT)n= 8, 53%. Median overall survival (OS) from CM diagnosis was 95 months, with an estimated 5-year survival rate of 77%, with a 5-year OS from NEN diagnosis of 87%.Conclusions:CM in NEN are rare and often clinically silent, with SSTR PET/CT proving essential for detection. While treatment adjustments were frequently observed, particularly with PRRT, OS remained favorable, indicating that the presence of CM in NEN serves as an indicator of metastatic spread rather than a standalone diagnostic determinant of survival. Larger, prospective studies are needed to further validate these findings and to better define the clinical implications of CM in NEN.
背景/目的：心脏转移是神经内分泌肿瘤的一种罕见表现，其详细的临床特征及意义尚未得到充分研究。 方法：我们回顾性分析了在ENETS卓越中心接受治疗的1201例神经内分泌肿瘤患者，以评估心脏转移的患病率、临床特征及预后。通过多模态影像学检查（包括生长抑素受体正电子发射断层扫描/计算机断层扫描）在15例患者中检出心脏转移（患病率1.25%），其中93%为异时性转移。 结果：多数患者为分化良好的肿瘤（G1/G2级），原发部位以回肠最为常见。27%的心脏转移患者出现相关临床症状。在检出心脏转移后，73%的病例调整了治疗方案，其中最常见的是启动肽受体放射性核素治疗（n=8，占53%）。从心脏转移诊断起的中位总生存期为95个月，预估5年生存率为77%；而从神经内分泌肿瘤诊断起的5年总生存率为87%。 结论：神经内分泌肿瘤中的心脏转移较为罕见且常无临床症状，生长抑素受体正电子发射断层扫描/计算机断层扫描对其检测至关重要。尽管治疗调整较为常见（尤其是肽受体放射性核素治疗的应用），但患者总生存期仍较为理想，这表明心脏转移在神经内分泌肿瘤中更多是转移扩散的标志，而非独立的生存预后决定性因素。未来需要更大规模的前瞻性研究进一步验证这些发现，并更明确地界定心脏转移在神经内分泌肿瘤中的临床意义。
肿瘤(癌症)患者之家